Revolution Medicines, Inc.
NasdaqGS:RVMD Stok Raporu
Revolution Medicines Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6 Revolution Medicines şirketinin kazançları yıllık ortalama -40.7% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.3% oranında artan oldu. Gelirler yıllık ortalama 29.3% oranında azalan oldu.
Anahtar bilgiler
-40.7%
Kazanç büyüme oranı
Biotechs Sektör Büyümesi 17.0% Gelir büyüme oranı -29.3% Özkaynak getirisi -36.2% Net Marj -76,423.3% Son Kazanç Güncellemesi 30 Sep 2024
Yakın geçmiş performans güncellemeleri
Revolution Medicines, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31
First half 2024 earnings released: US$1.51 loss per share (vs US$1.64 loss in 1H 2023) Aug 08
Revolution Medicines, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Aug 01
First quarter 2024 earnings released: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023) May 09
Revolution Medicines, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Full year 2023 earnings: EPS and revenues miss analyst expectations Feb 27
Tüm güncellemeleri göster
CEO, President & Chairman exercised options and sold US$3.1m worth of stock Nov 11
CEO, President & Chairman recently sold US$550k worth of stock Nov 07
Consensus revenue estimates decrease by 57% Nov 05
CEO, President & Chairman notifies of intention to sell stock Nov 04
Revolution Medicines, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31
Chief Operating Officer notifies of intention to sell stock Oct 15
CEO, President & Chairman notifies of intention to sell stock Oct 03
Calculating The Intrinsic Value Of Revolution Medicines, Inc. (NASDAQ:RVMD) Sep 28
President of Research & Development notifies of intention to sell stock Sep 16
President of Research & Development notifies of intention to sell stock Aug 15
Consensus revenue estimates fall by 76% Aug 14
First half 2024 earnings released: US$1.51 loss per share (vs US$1.64 loss in 1H 2023) Aug 08 Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.
CEO, President & Chairman notifies of intention to sell stock Aug 04
Revolution Medicines, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Aug 01
Revolution Medicines, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024 Jul 16
CEO, President & Chairman notifies of intention to sell stock Jul 15
Revolution Medicines, Inc. Announces Publication Demonstrating Robust Anti-Tumor Activity of Ras(On) Inhibitors in Preclinical Models of Refractory Kras-Mutated Non-Small Cell Lung Cancer Jul 12
Now 31% overvalued after recent price rise Jul 09
CEO, President & Chairman notifies of intention to sell stock Jun 17
This Is Why Revolution Medicines, Inc.'s (NASDAQ:RVMD) CEO Compensation Looks Appropriate Jun 15
Revolution Medicines: On Hold Pending A Lower Entry Point Jun 04
Consensus revenue estimates decrease by 52%, EPS upgraded May 15
Price target increased by 7.8% to US$44.82 May 12
Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2024 May 10
First quarter 2024 earnings released: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023) May 09
Chief Financial Officer notifies of intention to sell stock May 06
Revolution Medicines, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Revolution Medicines, Inc., Annual General Meeting, Jun 20, 2024 Apr 28
Price target increased by 7.1% to US$41.58 Apr 19
Revolution Medicines: An Expensive Shot At A Massive Market Opportunity Apr 12
Price target increased by 7.7% to US$39.83 Apr 11
Chief Operating Officer notifies of intention to sell stock Mar 13 Revolution Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $124.825544 million. Mar 05
Consensus revenue estimates fall by 92% Mar 04
Revolution Medicines, Inc. Provides Earnings Guidance for Full Year 2024 Feb 29
Full year 2023 earnings: EPS and revenues miss analyst expectations Feb 27
New major risk - Revenue and earnings growth Feb 23
Revolution Medicines, Inc. to Report Q4, 2023 Results on Feb 26, 2024 Feb 21
Revolution Medicines Is Hard To Understand Feb 01
President of Research & Development notifies of intention to sell stock Dec 30
New major risk - Shareholder dilution Nov 14
Price target decreased by 7.0% to US$34.14 Nov 13
Consensus revenue estimates decrease by 31% Nov 13
Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders. Nov 11 Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders. Nov 10
Third quarter 2023 earnings released: US$0.99 loss per share (vs US$0.87 loss in 3Q 2022) Nov 07
Revolution Medicines, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Nov 01
Revolution Medicines, Inc. Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236 Oct 24
New major risk - Revenue and earnings growth Oct 23
Price target increased by 7.9% to US$37.14 Oct 23 Revolution Medicines, Inc. Provides Pipeline Updates
New minor risk - Share price stability Oct 14
President of Research & Development notifies of intention to sell stock Oct 13
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor Sep 20
Revolution Medicines, Inc. Resigns Eric T. Schmidt as Board of Directors Sep 08
CEO, President & Chairman notifies of intention to sell stock Sep 03
Consensus revenue estimates increase by 15%, EPS downgraded Aug 15
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09
Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2023 Aug 09
Here's Why We're Not Too Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Situation Aug 09
Revolution Medicines, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 04
President of Research & Development notifies of intention to sell stock Aug 03
Revolution Medicines, Inc. (NasdaqGS:RVMD) entered into a definitive agreement to acquire EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders. Aug 03
Price target increased by 9.4% to US$34.29 Aug 02 Revolution Medicines, Inc.(NasdaqGS:RVMD) dropped from Russell Small Cap Comp Value Index
Consensus revenue estimates decrease by 25% May 15
Some Analysts Just Cut Their Revolution Medicines, Inc. (NASDAQ:RVMD) Estimates May 13
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 10 Revolution Medicines, Inc. Announces Executives Appointment
We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth Apr 02
Consensus revenue estimates fall by 34% Mar 06
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 01
Price target increased by 9.0% to US$32.22 Feb 28
Revolution Medicines, Inc. Announces Publication Describing Design and Synthesis of RMC-5552 Dec 20
We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely Dec 20
Revolution Medicines, Inc. to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration Dec 09
Revolution Medicines, Inc. Updates Earnings Guidance for 2022 Dec 08
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 09
Revolution Medicines, Inc. Provides Earnings Guidance for the Full Year 2022 Nov 08
Revolution Medicines, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Nov 02
Chief Operating Officer notifies of intention to sell stock Oct 30
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor Sep 23
We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate Sep 15 Revolution Medicines, Inc. Announces Executive Changes
Revolution Medicines promotes Jack Anders to CFO Sep 02
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 10
New Forecasts: Here's What Analysts Think The Future Holds For Revolution Medicines, Inc. (NASDAQ:RVMD) Aug 10
Revolution Medicines, Inc. Provides Earnings Guidance for the Year 2022 Aug 10
Revolution Medicines nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi NasdaqGS:RVMD Gelir, gider ve kazançlar (USD Millions ) Tarih Gelir Kazançlar G+A Giderleri Ar-Ge Giderleri 30 Sep 24 1 -567 88 115 30 Jun 24 1 -519 79 76 31 Mar 24 5 -484 72 0 31 Dec 23 12 -436 62 0 30 Sep 23 26 -331 54 253 30 Jun 23 30 -296 49 154 31 Mar 23 35 -259 45 0 31 Dec 22 35 -249 41 0 30 Sep 22 30 -245 38 0 30 Jun 22 27 -224 36 0 31 Mar 22 27 -208 33 0 31 Dec 21 29 -187 30 0 30 Sep 21 29 -169 28 0 30 Jun 21 40 -143 25 0 31 Mar 21 42 -126 23 0 31 Dec 20 43 -110 21 0 30 Sep 20 46 -95 20 0 30 Jun 20 46 -85 18 0 31 Mar 20 48 -71 15 0 31 Dec 19 50 -62 12 0 30 Sep 19 48 -57 12 0 31 Dec 18 20 -49 9 0
Kaliteli Kazançlar: RVMD şu anda kârlı değil.
Büyüyen Kar Marjı: RVMD şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: RVMD kârlı değildir ve zararlar son 5 yılda yılda 40.7% oranında artmıştır.
Büyüme Hızlandırma: RVMD 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: RVMD kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: RVMD hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi 'ne ( -36.2% ) sahiptir.
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
